Issuu on Google+

ReportsnReports | Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018 GlobalData, the industry analysis specialist, has released its new report, “Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018�. The report is an essential source of information and analysis on the global angina pectoris therapeutics market. The report identifies the key trends shaping and driving the global angina pectoris therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global angina pectoris therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. The global Angina Pectoris Therapeutics Market valued $9,655.4m in 2010 and is estimated to reach a value of $12,707.4m by 2018, after increasing at a compound annual growth rate (CAGR) of 3.5%. The moderate growth in revenues is attributed to increase in prevalence of the disease and expected approval of first-in-class investigational therapies from the mature pipeline such as Generx and varespladib. However, if approved, these new products will be expensive as they possess novel mechanism of action with significant improvements in safety and efficacy over the currently marketed drugs. GlobalData analysed that the current competition in the angina pectoris market is weak and that the available treatment options are moderately successful in meeting the market demand. The products currently available in the market are associated with mediocre efficacy and safety profiles. Some of the serious side-effects associated with the current angina therapies are liver dysfunction, sexual dysfunction, headache, fatigue, bracycardia, worsening of heart failure, increased blood pressure and high mortality. In addition to this, the current treatments offer poor quality of life due to their lack of efficacy in reducing cardiovascular events and mortality. Because the products currently in the market do not serve the unmet need, the market continues to present opportunities for stronger pipeline candidates. The unmet needs in the angina market are considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles. The Angina pectoris pipeline is strong. The Angina pectoris developmental pipeline is strong with 13 products in various phases of clinical development. Phase III consists of three products. The pipeline is dominated by first-inclass molecules and certain late stage novel molecules are likely to offer better efficacy and safety over existing available drugs in the market. Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends). Scope The report provides information on the key drivers and challenges of the angina pectoris therapeutics market. Its scope includes - Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) angina pectoris therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.


- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as angiogenesis, cardiac If channel inhibitior, phospholipase A2 inhibitor, cardiac myosin activator, sodium current blocker, stem cell therapy, substance P inhibitor, VEGF-D gene therapy and so on. - Analysis of the current and future competition in the seven key countries angina pectoris therapeutics market. Key market players covered are Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the angina pectoris therapeutics market. - Analysis of key recent licensing and partnership agreements in angina pectoris therapeutics market. Reasons to buy: The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global angina pectoris therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global angina pectoris therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global angina pectoris therapeutics market landscape? – Identify, understand and capitalize. Table of Contents 1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 6 2 Angina Pectoris Therapeutics: Executive Summary 8 2.1 The Angina Pectoris Therapeutics Market Expected to Show Moderate Growth Until 2018 8 2.2 Weak Current Competition in Angina Pectoris Therapeutics Market 9 2.3 Strong Pipeline with Novel Therapies is Expected to Increase the Competition in Angina Pectoris Therapeutics Market 10 2.4 Generics will Continue to Dominate the Angina Pectoris Therapeutics Market within the Forecast Period 10 3 Angina Pectoris Therapeutics: Introduction 12 3.1 Disease Overview 12


3.2 Epidemiology 13 3.3 Etiology and Pathophysiology 14 3.3.1 Etiology of Angina Pectoris 14 3.3.2 Pathophysiology of Angina Pectoris 15 3.4 Signs and Symptoms 16 3.5 Diagnosis 16 3.6 Treatment and Management Options 17 3.6.1 Lifestyle Changes 17 3.6.2 Medical Treatment 18 3.6.3 Medical Procedures 18 3.6.4 Cardiac Rehabilitation 19 3.7 GlobalData Pipeline Report Guidance 19 4 Angina Pectoris Therapeutics: Market Characterization 21 4.1 Angina Pectoris Therapeutics Market Size (2005–2010) – Global 21 4.2 Angina Pectoris Therapeutics Market Forecast (2010–2018) – Global 22 4.3 Angina Pectoris Therapeutics Market Size (2005–2010) – The US 24 4.4 Angina Pectoris Therapeutics Market Forecast (2010–2018) – The US 25 4.5 Angina Pectoris Therapeutics Market Size (2005–2010) – France 26 4.6 Angina Pectoris Therapeutics Market Forecast (2010–2018) – France 27 4.7 Angina Pectoris Therapeutics Market Size (2005–2010) – Germany 28 4.8 Angina Pectoris Therapeutics Market Forecast (2010–2018) – Germany 29 4.9 Angina Pectoris Therapeutics Market Size (2005–2010) – Italy 30 4.10 Angina Pectoris Therapeutics Market Forecast (2010–2018) – Italy 31 4.11 Angina Pectoris Therapeutics Market Size (2005–2010) – Spain 32 4.12 Angina Pectoris Therapeutics Market Forecast (2010–2018) – Spain 33 4.13 Angina Pectoris Therapeutics Market Size (2005–2010) – The UK 34 4.14 Angina Pectoris Therapeutics Market Forecast (2010–2018) – The UK 35 4.15 Angina Pectoris Therapeutics Market Size (2005–2010) – Japan 36 4.16 Angina Pectoris Therapeutics Market Forecast (2010–2018) – Japan 37 4.17 Drivers and Barriers for the Angina Pectoris Therapeutics Market 38 4.17.1 Drivers for the Angina Pectoris Therapeutics Market 38 4.17.2 Barriers for the Angina Pectoris Therapeutics Market 39 4.18 Opportunity and Unmet Need 39 4.19 Key Takeaway 41 5 Angina Pectoris Therapeutics: Competitive Assessment 42 5.1 Overview 42 5.2 Strategic Competitor Assessment 42 5.3 Product Profile for the Major Marketed Products in the Angina Pectoris Therapeutics Market 43 5.3.1 Sodium Channel Current Inhibitor 43 5.3.2 Nitrates 45 5.3.3 Beta-adrenergic Receptor Blockers (Beta Blockers) 46 5.3.4 Calcium Channel Blockers 47 5.3.5 Angiotensin Converting Enzyme Inhibitor (ACE inhibitors) 48 5.3.6 Statins 49


5.3.7 Selective If Channel Inhibitor 50 5.3.8 Glycoprotein IIb/IIIa inhibitor 52 5.4 Key Takeaway 59 6 Angina Pectoris Therapeutics: Pipeline Assessment 60 6.1 Overview 60 6.2 Strategic Pipeline Assessment 60 6.3 Angina Pectoris Therapeutics – Pipeline Analysis by Clinical Phase of Development 60 6.3.1 Angina Pectoris Therapeutics – Phase III Clinical Pipeline 61 6.3.2 Angina Pectoris Therapeutics – Phase II Clinical Pipeline 61 6.3.3 Angina Pectoris Therapeutics – Phase I Clinical Pipeline 61 6.3.4 Angina Pectoris Therapeutics – Preclinical Phase Pipeline 62 6.4 Angina Pectoris Therapeutics – Pipeline by Mechanism of Action 62 6.5 Technology Trends Analytical Framework 63 6.6 Angina Pectoris Therapeutics – Most Promising Drugs in Clinical Development 65 6.7 Most Promising Drug Profiles 65 6.7.1 A-002 (Varespladib Methyl) 65 6.7.2 Capsaicin 67 6.7.3 Generx 67 6.8 Key Takeaway 70 7 Angina Pectoris Therapeutics: Clinical Trials Mapping 71 7.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 71 7.2 Clinical Trials by Phase of Clinical Development 72 7.3 Clinical Trials by Trial Status 73 7.4 Prominent Sponsors 74 7.5 Clinical Trials by Sponsors 75 7.6 Top Companies Participating in Angina Pectoris Therapeutics Clinical Trials 76 8 Angina Pectoris Therapeutics: Strategic Assessment 78 8.1 Key Events Impacting the Future Market 78 8.2 Future Market Competition Scenario 78 9 Angina Pectoris Therapeutics: Future Players 80 9.1 Introduction 80 9.2 Company Profiles 80 9.2.1 Anthera Pharmaceuticals 80 9.2.2 Cardium Therapeutics 81 9.2.3 CardioVascular BioTherapeutics 82 9.2.4 Cytokinetics 83 9.3 Other Companies in the Angina Pectoris Therapeutics Market 85 9.4 Key Takeaway 85 10 Angina Pectoris Therapeutics: Licensing & Partnership Deals 86 11 Angina Pectoris Therapeutics: Appendix 88 11.1 Definitions 88 11.2 Acronyms 88 11.3 Research Methodology 90 11.3.1 Coverage 90


11.3.2 Secondary Research 90 11.3.3 Forecasting 91 11.3.4 Primary Research 93 11.3.5 Expert Panel Validation 94 11.4 Contact Us 94 11.5 Disclaimer 94 11.6 Bibliography 95 Latest Market Research Reports: Annual Forecasting Food & Grocery 2015 Global Small and Medium Scale LNG Industry Outlook to 2015 Offshore Wind Industry – Growth Potential Hampered by Issues in Supply Chain and Financing Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Drug Eluting Balloons (DEB) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Bronchitis Therapeutics- Pipeline Assessment and Market Forecasts to 2018 Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018

About Us: ReportsnReports.com is an online market research library of 135,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. Visit http://www.reportsnreports.com/ for more details.

Contact: Priyank Tiwari 7557 Rambler road, Suite 727, Dallas, TX 75231


Tel: +1-888-391-5441 sales@reportsandreports.com Visit our Market Research Blog @ http://www.reportsnreportsblog.com/ Connect with us on: Twitter @ http://www.twitter.com/marketsreports Facebook @ http://www.facebook.com/pages/ReportsnReports/191441427571689 LinkedIn @ http://www.linkedin.com/company/reportsnreports


ReportsnReports | Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018